Oncoinvent Advances Radspherin® Phase 2 Trial in Advanced Ovarian Cancer: What Investors Should Watch

Oncoinvent Asa (BRRGD) announced an update on their ongoing clinical study.

Study Overview
Oncoinvent ASA is running a Phase 2 trial to test Radspherin® in women with advanced ovarian and related cancers that have spread inside the abdomen. The official title describes a randomized, open-label, multicenter study of an intraperitoneal alpha-emitting therapy in patients receiving standard pre-surgery chemotherapy and interval debulking surgery. The main goal is to see if adding Radspherin® after surgery can lower the risk of cancer returning in the abdomen, which could improve long-term outcomes in a hard-to-treat patient group.

Intervention/Treatment
The treatment being tested is Radspherin®, a drug made of tiny biodegradable calcium carbonate particles that carry a short-lived radioactive substance. It is given directly into the abdominal cavity after surgery. The purpose is to kill remaining cancer cells that surgery and standard chemotherapy may miss, aiming to reduce microscopic disease and delay or prevent relapse.

Study Design
This is an interventional, randomized study with two groups run in parallel. One group receives standard care plus a single dose of Radspherin®, while the control group receives standard care alone. There is no masking; both doctors and patients know which treatment is given. The primary goal is preventive: to reduce the chance that cancer comes back in the abdomen after surgery and chemotherapy.

Study Timeline
The study was first submitted in July 2024, marking the formal start of regulatory tracking and site set-up. It is currently listed as recruiting, meaning patient enrollment is underway. The last update on ClinicalTrials was posted on 22 January 2026, showing that the sponsor continues to maintain and refine the trial record. Primary completion and overall completion dates are not yet reported, which is typical for a mid-stage study still building its patient cohort and follow-up period.

Market Implications
For investors, this update confirms that Oncoinvent is actively progressing a key asset in a large oncology market. Demonstrating benefit in advanced ovarian cancer could position Radspherin® as a valuable add-on to standard surgery and chemotherapy, potentially supporting future partnership interest or premium pricing if successful. The open-label, randomized design should produce decision-ready data for regulators and partners, though readouts are likely several years away. The radiopharmaceutical field is competitive, with larger players also advancing targeted therapies, but there are few direct intraperitoneal options in this indication. Continued trial activity may support sentiment around Oncoinvent’s pipeline, yet near-term stock performance will still hinge on financing, broader market risk appetite, and any interim safety or efficacy signals. Investors should treat this as a medium- to long-term catalyst rather than a near-term revenue driver.

The study remains ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about BRRGD’s potential, visit the Oncoinvent Asa drug pipeline page.